A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Treatment A (domperidone 10 mg)Drug: Treatment B (domperidone 20 mg)Drug: Treatment C (placebo)Drug: Treatment D (moxifloxacin)
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT01643889
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT01640080
A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01640093
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT01636557
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-39439335 10 mgDrug: JNJ-39439335 25 mgDrug: JNJ-39439335 50 mgDrug: Placebo
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 86
- Registration Number
- NCT01631487
A Study of Ketamine in Patients With Treatment-resistant Depression
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT01627782
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT01626651
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01615029
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3
Completed
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 578
- Registration Number
- NCT01611090
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01607762
© Copyright 2025. All Rights Reserved by MedPath